Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-70
SponsorXijing Hospital of Digestive Diseases

About this trial

The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are:

* Main indicators: the eradication rate of Helicobacter pylori for eradication. * Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.

Eligibility criteria

Qualifiers

Age 18-70 years, regardless of sex; chronic gastritis, peptic ulcer or dyspeptic symptoms, clear Hp infection (positive 13C-urea breath test); voluntary Hp eradication treatment; women of childbearing age are required to use a medically desirable form of contraception during the trial and for 1 month after the trial.

Disqualifiers

Have contraindications to the study drug or are allergic to the study drug; have taken a PPI within 2 weeks and an antibiotic or bismuth within 4 weeks; pregnant and lactating women; and Have undergone upper gastrointestinal surgery; refluse to sign the informed consent document.

Trial design

Treatments tested in this trial

  • Rabeprazloe+bismuth+amoxicillin+clarithromycin
  • Vonoprazan+amoxicillin+clarithromycin 14 days
  • Vonoprazan+amoxicillin+clarithromycin 7 days
  • Vonoprazan+tetracycline+furazolidone 14 days
  • Vonoprazan+tetracycline+furazolidone 7 days
  • Vonoprazan+amoxicillin+furazolidone 7 days
  • Vonoprazan+amoxicillin+tetracycline 14 days
  • Vonoprazan+amoxicillin 7 days
  • Vonoprazan+amoxicillin 14 days

Treatment groups

1,404 Participants
are divided into 9 treatment groups

9

Treatment groups

See each treatment group below.